Transplantation tolerance in an age of induced pluripotency

Current Opinion in Organ Transplantation

Volumn 14, Issue 4, 2009, Pages 321-325

  Fairchild, Paul J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cell replacement therapy; Induced pluripotent stem cells; Pluripotency; Tolerance

Indexed keywords

ADENOVIRUS VECTOR; LEVO IDURONIDASE; RECOMBINANT PROTEIN; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR;

CELL TYPE; DNA MODIFICATION; EMBRYONIC STEM CELL; HOMOLOGOUS RECOMBINATION; HUMAN; HURLER SYNDROME; IMMUNE RESPONSE; LYSOSOME STORAGE DISEASE; MEDICAL ETHICS; NEUROLOGIC DISEASE; NONHUMAN; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; REVIEW; STEM CELL TRANSPLANTATION; TRANSPLANTATION TOLERANCE;

ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; CELL SURVIVAL; EMBRYONIC STEM CELLS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE THERAPY; HUMANS; MICE; PLURIPOTENT STEM CELLS; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, AUTOLOGOUS;

EID: 68849095962     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32832e9424     Document Type: Review

References (45)

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282:1145-1147.
2. Fairchild PJ, Robertson NJ, Minger SL, Waldmann H. Embryonic stem cells: protecting pluripotency from alloreactivity. Curr Opin Immunol 2007; 19:596-602. (Pubitemid 47464918)
3. Fairchild PJ, Robertson NJ, Cartland S. Cell replacement therapy and the evasion of destructive immunity. Stem Cell Rev 2005; 1:159-167. (Pubitemid 43074201)
4. Gurdon JB, Melton DA. Nuclear reprogramming in cells. Science 2008; 322:1811-1815.
5. Nishikawa S, Goldstein RA, Nierras CR. The promise of human induced pluripotent stem cells for research and therapy. Nat Rev Mol Cell Biol 2008; 9:725-729.
6. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse fibroblasts and adult fibroblast cultures by defined factors. Cell 2006; 126:663-676. A landmark paper demonstrating the feasibility of reprogramming terminally differentiated adult cells to a state of pluripotency by the introduction of a cocktail of just four factors. (Pubitemid 44233629)
7. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007; 448:313-317. (Pubitemid 47080336)
8. Wernig M, Meissner A, Foreman R, et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007; 448:318-324.
9. Nakagawa M, Koyanagi M, Tanabe K, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008; 26:101-106.
10. Hanna J, Markoulaki S, Schorderet P, et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 2008; 133:250-264.
11. Aoi T, Yae K, Nakagawa M, et al. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 2008; 321:699-702.
12. Stadtfeld M, Brennand K, Hochedlinger K. Reprogramming of pancreatic β cells into induced pluripotent stem cells. Curr Biol 2008; 18:890-894.
13. Aasen T, Raya A, Barrero MJ, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 2008; 26:1276-1284.
14. Liu H, Zhu F, Yong J, et al. Generation of induced pluripotent stem cells from adult rhesus monkey fibroblasts. Cell Stem Cell 2008; 3:587-590.
15. Li W, Wei W, Zhu S, et al. Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 2009; 4:16-19.
16. Liao J, Cui C, Chen S, et al. Generation of induced pluripotent stem cell lines from adult rat cells. Cell Stem Cell 2009; 4:11-15.
17. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-872. This paper demonstrates how the principles of reprogramming, first defined using mouse cells, can be successfully adapted to the generation of iPSC using, as a starting population, cells of human origin. (Pubitemid 350138099)
18. Park I-H, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2007; 451:141-146.
19. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318:1917-1920.
20. Mauritz C, Schwanke K, Reppel M, et al. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation 2008; 118:507-517.
21. Narazaki G, Uosaki H, Teranishi M, et al. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation 2008; 118:498-506.
22. Kim JB, Zaehres H, Wu G, et al. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 2008; 454:646-650.
23. Feng B, Ng J-H, Heng J-CD, Ng H-H. Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. Cell Stem Cell 2009; 4:301-312.
24. Shi Y, Desponts C, Do JT, et al. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 2008; 3:568-574.
25. Huangfu D, Maehr R, Guo W, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008; 26:795-797. (Pubitemid 351961456)
26. Huangfu D, Osafune K, Maehr R, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008; 26:1269-1275. An elegant study showing how critical transcription factors, required for the reprogramming of human cells to pluripotency, may be replaced with small molecule compounds, providing a rational strategy for overcoming some of the risks associated with genetic modification.
27. Stadtfeld M, Nagaya M, Utikal J, et al. Induced pluripotent stem cells generated without viral integration. Science 2008; 945-949.
28. Okita K, Nakagawa M, Hyenjong H, et al. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008; 322:949-953.
29. Kaji K, Norrby K, Paca A, et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009; 458:771-775.
30. Woltjen K, Michael IP, Mohseni P, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009; 458:766-770.
31. Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009; 4:381-384. This paper represents a significant breakthrough in the field by illustrating the feasibility of reprogramming somatic cells from the mouse by introducing recombinant proteins engineered to permit their access to the nucleus.
32. Amabile G, Meissner A. Induced pluripotent stem cells: current progress and potential for regenerative medicine. Trends Mol Med 2009; 15:59-68.
33. Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008; 321:1218-1221. This paper describes an important study reporting the first derivation of iPSC from an elderly patient suffering from a degenerative disease and their subsequent differentiation into the very cell type responsible for the disease state.
34. Ebert AD, Yu J, Rose FF, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009; 457:277-280. A landmark paper showing that cells differentiated from patient-specific iPSC faithfully recapitulate aspects of the disease phenotype in vitro, illustrating their importance as tools for screening of novel drug candidates.
35. Sendtner M. Tailor-made diseased neurons. Nature 2009; 457:269-270.
36. Park I-H, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells. Cell 2008; 134:877-886.
37. Soldner F, Hockemeyer D, Beard C, et al. Induced pluripotent stem cells free of viral reprogramming factors. Cell 2009; 136:964-977.
38. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPSC generated from autologous skin. Science 2007; 318:1920-1923. This elegant proof-of-principle study was the first to demonstrate the reversal of a congenital defect in a mouse model of disease by the genetic modification of iPSC from mice with sickle cell anaemia and their directed differentiation ex vivo into haematopoietic progenitors, capable of reconstituting the peripheral blood of recipients.
39. Xu D, Alipio Z, FinkLM, et al. Phenotypic correction of murine hemophiliaAusing an iPS cell-based therapy. Proc Natl Acad Sci U S A 2009; 106:808-813.
40. Wernig M, Zhao J-P, Pruszak J, et al. Neurons derived from reprogrammed fibroblasts functionally integrateintothefetal brainandimprovesymptomsof rats with Parkinson's disease. Proc Natl Acad Sci U S A 2008; 105:5856-5861. (Pubitemid 351758462)
41. Robertson NJ, Brook F, Gardner RL, et al. Embryonic stem cell-derived tissues are immunogenic but their innate immune privilege promotes the induction of tolerance. Proc Natl Acad Sci U S A 2007; 104:20920-20925.
42. Wang J, Lozier J, Johnson G, et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat Biotechnol 2008; 26:901-908.
43. Dickson P, Peinovich M, McEntee M, et al. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. J Clin Invest 2008; 118:2868-2876.
44. Schwartz PH, Brick DJ. Stem cell therapies for the lysosomal storage diseases - the quintessential neurodegenerative diseases. Curr Stem Cell Res Ther 2008; 3:88-98.
45. Lanza RP, Cibelli JB, West MD, et al. The ethical reasons for stem cell research. Science 2001; 292:1299. (Pubitemid 32476200)